These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 1419336

  • 1. [A history and prospect of adoptive immunotherapy against malignant glioma--past, now and future].
    Nitta T.
    No To Shinkei; 1992 Jul; 44(7):605-13. PubMed ID: 1419336
    [No Abstract] [Full Text] [Related]

  • 2. [Cellular immunotherapy for malignant glioma].
    Okamoto Y, Yamashita J.
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
    [No Abstract] [Full Text] [Related]

  • 3. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
    Blacklock JB, Grimm EA.
    Immunol Ser; 1989 Sep; 48():93-9. PubMed ID: 2488328
    [No Abstract] [Full Text] [Related]

  • 4. Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors.
    Lillehei KO, Johnson SD, McCleary EL, Mitchell DH, Schiltz PM, Kruse CA.
    Online J Curr Clin Trials; 1993 Dec 29; Doc No 111():[806 words; 5 paragraphs]. PubMed ID: 8305997
    [No Abstract] [Full Text] [Related]

  • 5. Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma.
    Thomas C, Schober R, Lenard HG, Lumenta CB, Jacques DB, Wechsler W.
    Neuropediatrics; 1992 Jun 29; 23(3):123-5. PubMed ID: 1641079
    [Abstract] [Full Text] [Related]

  • 6. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ, Barth RF, Clendenon NR, Gordon WA.
    Cancer Res; 1990 Jul 15; 50(14):4338-43. PubMed ID: 2364388
    [Abstract] [Full Text] [Related]

  • 7. [Our experience with lymphocytes activated against cancer: CTL cells].
    Marcellino LR, Vinciguerra M, Marcellino MV, Sessa E.
    G Chir; 1997 Oct 15; 18(10):605-7. PubMed ID: 9479972
    [Abstract] [Full Text] [Related]

  • 8. The cellular immunotherapy of primary brain tumors.
    Hayes RL.
    Rev Neurol (Paris); 1992 Oct 15; 148(6-7):454-66. PubMed ID: 1448666
    [Abstract] [Full Text] [Related]

  • 9. Rat mitogen-stimulated lymphokine-activated T killer cells: production and effects on C6 glioma cells in vitro and in vivo in the brain of Wistar rats.
    Carson WE, Jakowatz JG, Yamamoto R, Fitzgerald T, Gupta S, Vayuvegula B, Lucci JA, Beckman MT, Dulkanchainun S, Granger GA.
    J Immunother (1991); 1991 Apr 15; 10(2):131-40. PubMed ID: 2043593
    [Abstract] [Full Text] [Related]

  • 10. Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins.
    Zanovello P, Rosato A, Bronte V, Cerundolo V, Collavo D.
    Ann Ist Super Sanita; 1991 Apr 15; 27(1):91-5. PubMed ID: 1958033
    [Abstract] [Full Text] [Related]

  • 11. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T, Monden M, Takeda T, Gotoh M, Sakon M, Umeshita K, Hasuike Y, Sakita I, Nakano H, Yoshida T.
    Gan To Kagaku Ryoho; 1993 Aug 15; 20(11):1457-60. PubMed ID: 8396896
    [Abstract] [Full Text] [Related]

  • 12. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT, Kradin RL.
    Allergol Immunopathol (Madr); 1991 Aug 15; 19(5):209-14. PubMed ID: 1811418
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
    Toh U, Yamana H, Kido K, Mine T, Fujii T, Horiuchi H, Sasatomi T, Ishibashi N, Yutani S, Fujita H, Shirouzu K.
    Gan To Kagaku Ryoho; 2003 Oct 15; 30(11):1566-70. PubMed ID: 14619465
    [Abstract] [Full Text] [Related]

  • 15. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
    Yoshida S, Takai N, Ono K, Saito T, Tanaka R.
    No To Shinkei; 1988 Feb 15; 40(2):119-25. PubMed ID: 3259433
    [Abstract] [Full Text] [Related]

  • 16. [Augmentation of therapeutic effect of adoptive immunotherapy through a synergy between transferred killer cells and host's fresh lymphocytes].
    Kan N, Yamasaki S, Harada T, Satoh K, Ichinose Y, Moriguchi Y, Kodama H, Ohgaki K.
    Hum Cell; 1992 Sep 15; 5(3):236-42. PubMed ID: 1467322
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
    Munari L, Silvani A, Passerini CG, Radrizzani M, Parmiani G, Boiardi A.
    J Neurosurg Sci; 1990 Sep 15; 34(3-4):283-8. PubMed ID: 1965907
    [Abstract] [Full Text] [Related]

  • 20. Clinical use of interleukin-2 in treating cancer.
    Patterson DL, Wiemann MC.
    Indiana Med; 1991 Aug 15; 84(8):534-7. PubMed ID: 1918915
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.